Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Blood Cancer J ; 14(1): 100, 2024 Jun 20.
Article in English | MEDLINE | ID: mdl-38902256

ABSTRACT

Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an integrative multiomic approach to identify a signature at diagnosis that will identify DLBCL at high risk of early clinical failure. Tumor biopsies from 444 newly diagnosed DLBCL were analyzed by WES and RNAseq. A combination of weighted gene correlation network analysis and differential gene expression analysis was used to identify a signature associated with high risk of early clinical failure independent of IPI and COO. Further analysis revealed the signature was associated with metabolic reprogramming and identified cases with a depleted immune microenvironment. Finally, WES data was integrated into the signature and we found that inclusion of ARID1A mutations resulted in identification of 45% of cases with an early clinical failure which was validated in external DLBCL cohorts. This novel and integrative approach is the first to identify a signature at diagnosis, in a real-world cohort of DLBCL, that identifies patients at high risk for early clinical failure and may have significant implications for design of therapeutic options.


Subject(s)
Lymphoma, Large B-Cell, Diffuse , Humans , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/diagnosis , Male , Female , Gene Expression Profiling , Middle Aged , Transcriptome , Mutation , Gene Expression Regulation, Neoplastic , Transcription Factors/genetics , Biomarkers, Tumor/genetics , Aged , Prognosis , Tumor Microenvironment , Exome Sequencing , Adult , DNA-Binding Proteins/genetics , Treatment Failure
2.
Cell Rep Med ; 5(3): 101443, 2024 Mar 19.
Article in English | MEDLINE | ID: mdl-38428430

ABSTRACT

Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma of germinal center origin, which presents with significant biologic and clinical heterogeneity. Using RNA-seq on B cells sorted from 87 FL biopsies, combined with machine-learning approaches, we identify 3 transcriptional states that divide the biological ontology of FL B cells into inflamed, proliferative, and chromatin-modifying states, with relationship to prior GC B cell phenotypes. When integrated with whole-exome sequencing and immune profiling, we find that each state was associated with a combination of mutations in chromatin modifiers, copy-number alterations to TNFAIP3, and T follicular helper cells (Tfh) cell interactions, or primarily by a microenvironment rich in activated T cells. Altogether, these data define FL B cell transcriptional states across a large cohort of patients, contribute to our understanding of FL heterogeneity at the tumor cell level, and provide a foundation for guiding therapeutic intervention.


Subject(s)
Lymphoma, B-Cell , Lymphoma, Follicular , Humans , Lymphoma, Follicular/genetics , Lymphoma, Follicular/pathology , Tumor Microenvironment/genetics , Lymphoma, B-Cell/genetics , B-Lymphocytes , Chromatin
3.
Antimicrob Agents Chemother ; 68(3): e0149723, 2024 Mar 06.
Article in English | MEDLINE | ID: mdl-38358266

ABSTRACT

Bacillus anthracis is a Gram-positive Centers for Disease Control and Prevention category "A" biothreat pathogen. Without early treatment, inhalation of anthrax spores with progression to inhalational anthrax disease is associated with high fatality rates. Gepotidacin is a novel first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is being evaluated for use against biothreat and conventional pathogens. Gepotidacin selectively inhibits bacterial DNA replication via a unique binding mode and has in vitro activity against a collection of B. anthracis isolates including antibacterial-resistant strains, with the MIC90 ranging from 0.5 to 1 µg/mL. In vivo activity of gepotidacin was also evaluated in the New Zealand White rabbit model of inhalational anthrax. The primary endpoint was survival, with survival duration and bacterial clearance as secondary endpoints. The trigger for treatment was the presence of anthrax protective antigen in serum. New Zealand White rabbits were dosed intravenously for 5 days with saline or gepotidacin at 114 mg/kg/d to simulate a dosing regimen of 1,000 mg intravenous (i.v.) three times a day (TID) in humans. Gepotidacin provided a survival benefit compared to saline control, with 91% survival (P-value: 0.0001). All control animals succumbed to anthrax and were found to be blood- and organ culture-positive for B. anthracis. The novel mode of action, in vitro microbiology, preclinical safety, and animal model efficacy data, which were generated in line with Food and Drug Administration Animal Rule, support gepotidacin as a potential treatment for anthrax in an emergency biothreat situation.


Subject(s)
Acenaphthenes , Anthrax Vaccines , Anthrax , Bacillus anthracis , Heterocyclic Compounds, 3-Ring , Respiratory Tract Infections , Rabbits , Humans , Animals , Anthrax/microbiology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Disease Models, Animal , Anthrax Vaccines/therapeutic use
5.
medRxiv ; 2023 Jun 10.
Article in English | MEDLINE | ID: mdl-37333387

ABSTRACT

PURPOSE: 60-70% of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients avoid events within 24 months of diagnosis (EFS24) and the remainder have poor outcomes. Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an integrative multiomic approach to identify a signature at diagnosis that will identify DLBCL at high risk of early clinical failure. PATIENTS AND METHODS: Tumor biopsies from 444 newly diagnosed DLBCL were analyzed by WES and RNAseq. A combination of weighted gene correlation network analysis and differential gene expression analysis followed by integration with clinical and genomic data was used to identify a multiomic signature associated with high risk of early clinical failure. RESULTS: Current DLBCL classifiers are unable to discriminate cases who fail EFS24. We identified a high risk RNA signature that had a hazard ratio (HR, 18.46 [95% CI 6.51-52.31] P < .001) in a univariate model, which did not attenuate after adjustment for age, IPI and COO (HR, 20.8 [95% CI, 7.14-61.09] P < .001). Further analysis revealed the signature was associated with metabolic reprogramming and a depleted immune microenvironment. Finally, WES data was integrated into the signature and we found that inclusion of ARID1A mutations resulted in identification of 45% of cases with an early clinical failure which was validated in external DLBCL cohorts. CONCLUSION: This novel and integrative approach is the first to identify a signature at diagnosis that will identify DLBCL at high risk for early clinical failure and may have significant implications for design of therapeutic options.

6.
Talanta ; 260: 124653, 2023 Aug 01.
Article in English | MEDLINE | ID: mdl-37178676

ABSTRACT

Alkenones are among the most widely used paleotemperature biomarkers. Traditionally, alkenones are analyzed using gas chromatography-flame ionization detector (GC-FID), or GC-chemical ionization-mass spectrometry (GC-CI-MS). However, these methods encounter considerable challenges for samples that exhibit matrix interference or low concentrations, with GC-FID requiring tedious sample preparations and GC-CI-MS suffering from nonlinear response and a narrow linear dynamic range. Here we demonstrate that reversed-phase high pressure liquid chromatography-mass spectrometry (HPLC-MS) methods provide excellent resolution, selectivity, linearity and sensitivity for alkenones in complex matrices. We systematically compared the advantages and limitations of three mass detectors (quadrupole, Orbitrap, and quadrupole-time of flight) and two ionization modes (electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI)) for alkenone analyses. We demonstrate that ESI performs better than APCI as response factors of various unsaturated alkenones are similar. Among the three mass analyzers tested, orbitrap MS provided the lowest limit of detection (0.4, 3.8 and 8.6 pg injected masses for Orbitrap, qTOF and single quadrupole MS, respectively) and the widest linear dynamic range (600, 20 and 30 folds for Orbitrap, qTOF and single quadrupole MS, respectively). Single quadrupole MS operated in ESI mode provides accurate quantification of proxy measurements over a wide range of injection masses, and with its modest instrument cost, represents an ideal method for routine applications. Analysis of global core-top sediment samples confirmed the efficacy of HPLC-MS methods for the detection and quantification of paleotemperature proxies based on alkenones and their superiority over GC-based methods. The analytical method demonstrated in this study should also allow highly sensitive analyses of diverse aliphatic ketones in complex matrices.

7.
Hematol Oncol ; 41(4): 644-654, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37254453

ABSTRACT

Non-follicular low-grade B-cell lymphomas (LGBCL) are biologically diverse entities that share clinical and histologic features that make definitive pathologic categorization challenging. While most patients with LGBCL have an indolent course, some experience aggressive disease, highlighting additional heterogeneity across these subtypes. To investigate the potential for shared biology across subtypes, we performed RNA sequencing and applied machine learning approaches that identified five clusters of patients that grouped independently of subtype. One cluster was characterized by inferior outcome, upregulation of cell cycle genes, and increased tumor immune cell content. Integration of whole exome sequencing identified novel LGBCL mutations and enrichment of TNFAIP3 and BCL2 alterations in the poor survival cluster. Building on this, we further refined a transcriptomic signature associated with early clinical failure in two independent cohorts. Taken together, this study identifies unique clusters of LGBCL defined by novel gene expression signatures and immune profiles associated with outcome across diagnostic subtypes.


Subject(s)
Lymphoma, B-Cell , Humans , Lymphoma, B-Cell/pathology , Gene Expression Profiling , Transcriptome
8.
Antimicrob Agents Chemother ; 67(5): e0138122, 2023 05 17.
Article in English | MEDLINE | ID: mdl-37097147

ABSTRACT

Francisella tularensis (F. tularensis) is a Centers for Disease Control (CDC) category "A" Gram-negative biothreat pathogen. Inhalation of F. tularensis can cause pneumonia and respiratory failure and is associated with high mortality rates without early treatment. Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action. Gepotidacin selectively inhibits bacterial DNA replication via a unique binding mode, has activity against multidrug-resistant target pathogens, and has demonstrated in vitro activity against diverse collections of F. tularensis isolates (MIC90 of 0.5 to 1 µg/mL). Gepotidacin was evaluated in the cynomolgus macaque model of inhalational tularemia, using the SCHU S4 strain, with treatment initiated after exposure and sustained fever. Macaques were dosed via intravenous (i.v.) infusion with saline or gepotidacin at 72 mg/kg/day to support a human i.v. infusion dosing regimen of 1,000 mg three times daily. The primary study endpoint was survival, with survival duration and bacterial clearance as secondary endpoints. Gepotidacin treatment resulted in 100% survival compared to 12.5% in the saline-treated control group (P < 0.0001) at Day 43 postinhalational challenge. All gepotidacin-treated animals were blood and organ culture negative for F. tularensis at the end of the study. In contrast, none of the saline control animals were blood and organ culture negative. Gepotoidacin's novel mechanism of action and the efficacy data reported here (aligned with the Food and Drug Administration Animal Rule) support gepotidacin as a potential treatment for pneumonic tularemia in an emergency biothreat situation.


Subject(s)
Francisella tularensis , Tularemia , Animals , Humans , Tularemia/microbiology , Disease Models, Animal , Macaca fascicularis , Bacterial Vaccines
9.
Clin Cancer Res ; 29(5): 957-970, 2023 03 01.
Article in English | MEDLINE | ID: mdl-36534518

ABSTRACT

PURPOSE: IgM monoclonal gammopathy of undetermined significance (MGUS) and Waldenström macroglobulinemia (WM) represent a disease spectrum with highly varied therapeutic management, ranging from observation to chemoimmunotherapy. The current classification relies solely on clinical features and does not explain the heterogeneity that exists within each of these conditions. Further investigation is warranted to shed light on the biology that may account for the clinical differences. EXPERIMENTAL DESIGN: We used bone marrow (BM) clonal CD19+ and/or CD138+ sorted cells, matched BM supernatant, and peripheral blood serum from 32 patients (7 MGUS, 25 WM) to perform the first multi-omics approach including whole-exome sequencing, RNA sequencing, proteomics, metabolomics, and mass cytometry. RESULTS: We identified three clusters with distinct pathway activation, immune content, metabolomic, and clinical features. Cluster 1 included only patients with WM and was characterized by transcriptional silencing of genes involved in cell cycle and immune response, enrichment of mitochondrial metabolism, infiltration of senescent T effector memory cells, and aggressive clinical behavior. Genetic/structural alterations of TNFAIP3 were distinct events of this cluster. Cluster 2 comprised both MGUS and WM patients with upregulation of inflammatory response, senescence and glycolysis signatures, increased activated T follicular helper and T regulatory cells, and indolent clinical behavior. Cluster 3 also included both MGUS and WM patients and exhibited intermediate features, including proliferative and inflammatory signaling, as well as glycolysis and mitochondrial metabolism. CONCLUSIONS: We have identified three distinct molecular clusters, suggesting a potential biologic classification that may have therapeutic implications.


Subject(s)
Monoclonal Gammopathy of Undetermined Significance , Waldenstrom Macroglobulinemia , Humans , Immunoglobulin M , Monoclonal Gammopathy of Undetermined Significance/genetics , Adaptor Proteins, Signal Transducing , Signal Transduction
10.
Viruses ; 14(10)2022 10 18.
Article in English | MEDLINE | ID: mdl-36298846

ABSTRACT

The Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, recognizes that the evaluation of medical countermeasures under the Animal Rule requires well-characterized and reproducible animal models that are likely to be predictive of clinical benefit. Marburg virus (MARV), one of two members of the genus Marburgvirus, is characterized by a hemorrhagic fever and a high case fatality rate for which there are no licensed vaccines or therapeutics available. This natural history study consisted of twelve cynomolgus macaques challenged with 1000 PFU of MARV Angola and observed for body weight, temperature, viremia, hematology, clinical chemistry, and coagulation at multiple time points. All animals succumbed to disease within 8 days and exhibited signs consistent with those observed in human cases, including viremia, fever, systemic inflammation, coagulopathy, and lymphocytolysis, among others. Additionally, this study determined the time from exposure to onset of disease manifestations and the time course, frequency, and magnitude of the manifestations. This study will be instrumental in the design and development of medical countermeasures to Marburg virus disease.


Subject(s)
Marburg Virus Disease , Marburgvirus , Medical Countermeasures , Humans , Animals , Marburgvirus/physiology , Viremia , Macaca fascicularis
11.
Toxicol Appl Pharmacol ; 430: 115680, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34411581

ABSTRACT

Cyclocreatine (LUM-001) was evaluated for chronic toxicity (23 weeks) in beagle dogs to support clinical development in patients with creatine transporter deficiency (CTD) disorder. Deionized water (vehicle control) or cyclocreatine was administered by oral gavage twice daily (12 ± 1 h apart) at 20, 40 and 75 mg/kg/dose followed by a recovery period. Due to severe toxicity, the study was terminated earlier than the planned 39 weeks of dosing. Animals in the 20, 40 and 75 mg/kg/dose groups completed 160, 106, and 55 days of dosing, respectively, followed by 30, 55 and 106 days of a recovery period, respectively. Three (25%), 7 (58%), and 7 (58%) animals were euthanized and/or found dead in the 40, 80, and 150 mg/kg/day dose groups, respectively. Clinical signs observed were inappetence, frequent emesis, stool abnormalities, weight loss, lethargy and respiratory distress. Histopathological evaluation revealed congestion, edema, cellular infiltration, fibrin, and/or hemorrhage in the lungs of all dose groups. Additionally, animals in all cyclocreatine treatment groups had perinuclear cytoplasmic vacuoles in the heart, kidneys, skeletal and smooth muscles. After the recovery period, the vacuoles were still observed in the cardiac and renal tissues. Cyclocreatine was absorbed rapidly with mean Tmax within 1 to 2 h and half-life ranged between 2.17 and 2.79 h on Day 1, however, on the final day of dosing, it ranged between 5.80 and 8.77 h (males) and 10.3 to 13.1 h (females). To conclude, in this study the lungs, kidneys, heart, skeletal and smooth muscles were identified as the target organs of cyclocreatine toxicity in beagle dogs.


Subject(s)
Creatinine/analogs & derivatives , Toxicity Tests, Chronic , Administration, Oral , Animals , Creatinine/administration & dosage , Creatinine/pharmacokinetics , Creatinine/toxicity , Dogs , Dose-Response Relationship, Drug , Female , Half-Life , Kidney/drug effects , Kidney/pathology , Lung/drug effects , Lung/pathology , Lung/physiopathology , Lung Diseases/chemically induced , Lung Diseases/pathology , Lung Diseases/physiopathology , Male , Muscle, Skeletal/drug effects , Muscle, Skeletal/pathology , Muscle, Smooth/drug effects , Muscle, Smooth/pathology , Myocardium/pathology , No-Observed-Adverse-Effect Level , Risk Assessment , Time Factors , Toxicokinetics , Vacuoles/drug effects , Vacuoles/pathology
12.
Nat Commun ; 12(1): 15, 2021 01 04.
Article in English | MEDLINE | ID: mdl-33397905

ABSTRACT

Alkenones are biomarkers produced solely by algae in the order Isochrysidales that have been used to reconstruct sea surface temperature (SST) since the 1980s. However, alkenone-based SST reconstructions in the northern high latitude oceans show significant bias towards warmer temperatures in core-tops, diverge from other SST proxies in down core records, and are often accompanied by anomalously high relative abundance of the C37 tetra-unsaturated methyl alkenone (%C37:4). Elevated %C37:4 is widely interpreted as an indicator of low sea surface salinity from polar water masses, but its biological source has thus far remained elusive. Here we identify a lineage of Isochrysidales that is responsible for elevated C37:4 methyl alkenone in the northern high latitude oceans through next-generation sequencing and lab-culture experiments. This Isochrysidales lineage co-occurs widely with sea ice in marine environments and is distinct from other known marine alkenone-producers, namely Emiliania huxleyi and Gephyrocapsa oceanica. More importantly, the %C37:4 in seawater filtered particulate organic matter and surface sediments is significantly correlated with annual mean sea ice concentrations. In sediment cores from the Svalbard region, the %C37:4 concentration aligns with the Greenland temperature record and other qualitative regional sea ice records spanning the past 14 kyrs, reflecting sea ice concentrations quantitatively. Our findings imply that %C37:4 is a powerful proxy for reconstructing sea ice conditions in the high latitude oceans on thousand- and, potentially, on million-year timescales.

13.
Regul Toxicol Pharmacol ; 117: 104750, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32745584

ABSTRACT

Cyclocreatine (LUM-001), a creatine analog, was evaluated for its nonclinical toxicity in Sprague Dawley (SD) rats. Deionized water as a vehicle control article or cyclocreatine was administered by oral gavage twice daily (approximately 12 ± 1 h apart) at 30, 100 and 300 mg/kg/dose levels in rats up to 26 weeks followed by a 28-day recovery period. Due to an increased incidence of seizures, the 600 mg/kg/day dose group males were dosed only for 16-weeks followed by a 14-week recovery period. Thirteen males and four females from 600 mg/kg/day dose group were sacrificed at interim on Day 113 to study plausible brain lesions and not due to moribundity. There was a dose dependent increase in the number of seizure incidences in ≥60 mg/kg/day males and 600 mg/kg/day females. Microscopically, higher incidences of vacuoles in the brain at 600 mg/kg/day in both sexes, thyroid follicular atrophy and follicular cell hypertrophy at ≥200 mg/kg/day in males and 600 mg/kg/day in females, and seminiferous tubular degeneration and/or interstitial edema in testes at ≥200 mg/kg/day were observed. Mean plasma half-life of cyclocreatine was between 3.5 and 6.5 h. In conclusion, chronic administration of cyclocreatine by oral gavage in Sprague Dawley rats induced the seizures and microscopic lesions in the brain, testes and thyroid. Based on the results of this study the highest tested dose of 600 mg/kg/day (mean Cmax of 151.5 µg/mL; AUC0-24 of 1970 h*µg/mL) was considered the maximum tolerated dose (MTD) in SD rats.


Subject(s)
Brain/drug effects , Creatinine/analogs & derivatives , Toxicity Tests, Chronic/methods , Administration, Oral , Animals , Brain/metabolism , Brain/pathology , Creatine/analogs & derivatives , Creatine/blood , Creatine/toxicity , Creatinine/administration & dosage , Creatinine/blood , Creatinine/toxicity , Female , Male , Organ Size/drug effects , Organ Size/physiology , Rats , Rats, Sprague-Dawley , Testis/drug effects , Testis/metabolism , Testis/pathology , Thyroid Gland/drug effects , Thyroid Gland/metabolism , Thyroid Gland/pathology , Time Factors
14.
Vet Clin Pathol ; 49(3): 382-388, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32686179

ABSTRACT

A 5.25-year-old cynomolgus macaque (Macaca fascicularis) was found to have a marked leukocytosis due to a lymphocytosis on routine quarantine laboratory data prior to inclusion in a preclinical research study. The majority of lymphocytes were characterized as intermediate to large with round to convoluted nuclei, coarse to clumped chromatin, rare prominent nucleoli, and moderate amounts of lightly basophilic cytoplasm that frequently contained small magenta granules and/or clear vacuoles. The animal had tested negative for several viruses and other etiologic agents found in nonhuman primates 1 week prior to shipment to the research facility. However, further evaluation of the blood smear revealed rare hemoflagellates, and later testing using real-time PCR and ELISA was confirmatory for Trypanosoma cruzi (T cruzi). Trypanosoma cruzi is a zoonotic pathogen responsible for Chagas disease in people and can have negative consequences on study results when positive animals are inadvertently used for preclinical research. This case report describes a marked large granular lymphocytosis in an otherwise healthy macaque as the only indication of infection with T cruzi in an animal believed to be negative for the infection. Additionally, it highlights the diagnostic limitations of screening tests to rule out diseases in animals intended to be used in preclinical studies.


Subject(s)
Chagas Disease , Leukemia, Large Granular Lymphocytic , Trypanosoma cruzi , Animals , Chagas Disease/diagnosis , Chagas Disease/veterinary , Enzyme-Linked Immunosorbent Assay/veterinary , Leukemia, Large Granular Lymphocytic/veterinary , Macaca fascicularis
15.
Int J Toxicol ; : 1091581820941412, 2020 Jul 21.
Article in English | MEDLINE | ID: mdl-32691648

ABSTRACT

AV7909 is a next-generation anthrax vaccine candidate indicated for post-exposure prophylaxis of exposure to Bacillus anthracis. AV7909 consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and the immunostimulatory Toll-like receptor 9 agonist oligodeoxynucleotide adjuvant, CPG 7909. Safety testing for pediatric population is warranted to support the potential emergency use of AV7909 in children. This study was conducted to investigate the local tolerance and potential systemic toxicity and their reversibility in juvenile rats by repeat intramuscular injections of the AV7909 vaccine candidate. Animals were dosed on postnatal day (PND) 21 (at weaning), PND 28, and PND 35, with the test article (AV7909), the adjuvant alone (Alhydrogel + CPG 7909), or sterile water for injection. Core group animals were necropsied on PND 37 and recovery group on PND 49. Study end points included survival, clinical observations, injection site observations, body weights, clinical pathology (hematology, coagulation, and clinical chemistry), pro-inflammatory biomarker analysis (alpha-2 macroglobulin [A2M] and alpha-1 acid glycoprotein [AGP]), and anatomic pathology. Immune response to vaccination was measured using the high-throughput anthrax lethal toxin neutralization assay (htpTNA). The AV7909 vaccine candidate produced no apparent systemic or local toxicity. The AGP and A2M levels were elevated in both the adjuvant-alone and AV7909 groups at the end of treatment but were comparable to control levels by the end of the recovery period. All animals in the AV7909 group demonstrated a robust neutralizing antibody response. The results indicate that AV7909 has a favorable safety profile in juvenile rats.

16.
Regul Toxicol Pharmacol ; 109: 104483, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31580887

ABSTRACT

JD5037 is a novel peripherally restricted CB1 receptor (CB1R) inverse agonist being developed for the treatment of visceral obesity and its metabolic complications, including nonalcoholic fatty liver disease and dyslipidemia. JD5037 was administered by oral gavage at 10, 40, and 150 mg/kg/day dose levels for up to 34 days to Sprague Dawley rats, and at 5, 20, and 75 mg/kg/day dose levels for 28 consecutive days to Beagle dogs. In rats, higher incidences of stereotypic behaviors were observed in 10 mg/kg females and 40 mg/kg males, and slower responses for reflex and sensory tests were observed only in males at 10 and 40 mg/kg during neurobehavioral testing. Sporadic minimal incidences of decreased activity (males) and seizures (both sexes) were observed in rats during daily clinical observations, without any clear dose-relationship. Male dogs at 75 mg/kg during treatment period, but not recovery period, had an increased incidence of gut associated lymphoid tissue hyperplasia and inflammation in the intestine. In both species, highest dose resulted in lower AUCs indicative of non-linear kinetics. Free access to food increased the plasma AUC∞ by ~4.5-fold at 20 mg/kg in dogs, suggesting presence of food may help in systemic absorption of JD5037 in dogs. Based on the study results, 150 mg/kg/day in rats, and 20 and 75 mg/kg/day doses in male and female dogs, respectively, were determined to be the no-observed-adverse-effect-levels (NOAELs).


Subject(s)
Drugs, Investigational/toxicity , Pyrazoles/toxicity , Receptor, Cannabinoid, CB1/agonists , Seizures/chemically induced , Stereotyped Behavior/drug effects , Sulfonamides/toxicity , Animals , Area Under Curve , Behavior, Animal/drug effects , Disease Models, Animal , Dogs , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Drugs, Investigational/therapeutic use , Female , Humans , Investigational New Drug Application , Male , No-Observed-Adverse-Effect Level , Non-alcoholic Fatty Liver Disease/drug therapy , Pyrazoles/pharmacokinetics , Pyrazoles/therapeutic use , Rats , Rats, Sprague-Dawley , Sex Factors , Sulfonamides/pharmacokinetics , Sulfonamides/therapeutic use
17.
Toxicol Sci ; 170(1): 234-246, 2019 07 01.
Article in English | MEDLINE | ID: mdl-30985877

ABSTRACT

The ICH revised the S3A guidance allowing blood to be microsampled for toxicokinetic analysis from the main study cohorts of rats in general toxicology studies. The resulting changes in the hemogram have been examined in healthy animals but the ability to read through the data when there are toxicological changes has not been thoroughly examined in the literature. To address this, a toxicology study in Sprague Dawley rats was conducted where animals received repeated doses of saline or valproic acid by IP injection daily for 7 days. Animals in both treatment groups were unbled, serially bled (6 bleeds/animal at 0.1 ml/bleed) or compositely bled (2 bleeds/animal at 0.6 ml/bleed) on days 1 and 7 for TK analysis. No statistically significant changes in the clinical pathology were observed for either the serial bleed or composite bleed animals when compared with their respective unbled control; however, a 4%-7% decrease in erythrocyte counts following serial bleeding and a 5%-19% decrease following composite bleeding was observed. When all the clinical pathology and organ weight data were equivalence tested, both the serial bleed and composite bleed results were equivalent to their unbled controls except for the erythroid parameters in the composite bleed group. Toxicokinetic analysis of the blood samples resulted in comparable concentration-time curves, regardless of the method of blood collection. Under these study conditions, the results show blood microsamples can be collected from the core or recovery cohort of animals in a toxicology study without impacting the toxicological interpretation in rats.


Subject(s)
Blood Volume , Phlebotomy/methods , Valproic Acid/blood , Valproic Acid/toxicity , Animals , Body Weight/drug effects , Data Interpretation, Statistical , Female , Hematologic Tests , Injections, Intraperitoneal , Male , Organ Size/drug effects , Rats, Sprague-Dawley , Sex Factors , Toxicokinetics
18.
Phys Rev Lett ; 119(11): 111602, 2017 Sep 15.
Article in English | MEDLINE | ID: mdl-28949212

ABSTRACT

The supersymmetrization of curvature squared terms is important in the study of the low-energy limit of compactified superstrings where a distinguished role is played by the Gauss-Bonnet combination, which is ghost-free. In this Letter, we construct its off-shell N=(1,0) supersymmetrization in six dimensions for the first time. By studying this invariant together with the supersymmetric Einstein-Hilbert term, we confirm and extend known results of the α^{'}-corrected string theory compactified to six dimensions. Finally, we analyze the spectrum about the AdS_{3}×S^{3} solution.

19.
Burns ; 40(4): 759-71, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24290856

ABSTRACT

Opioid-related side effects are problematic for burn patients. Dual mechanism therapeutics targeting opioid and non-opioid mechanisms may have reduced side effects with similar analgesic efficacy. Tramadol combines mu opioid receptor agonism with norepinephrine reuptake inhibition and has been effective in treating some types of pain. The effectiveness of tramadol in treating pain associated with burns is unclear. We hypothesized that tramadol is effective in reducing thermal injury-evoked pain behaviors in a rat model. Rats were anesthetized and a 100°C metal probe was placed on the hindpaw for 30 s to induce a full thickness thermal injury. A subset of rats was perfusion fixed and hindpaw tissue and spinal cord collected for anatomical analysis. Rats received morphine (5 mg/kg; i.p.), tramadol (10-30 mg/kg; i.p.) or vehicle and latency to paw withdrawal from a noxious thermal or non-noxious mechanical stimulus was recorded every 10 min over 70 min and again at 2 h. We report that pain behaviors developed within 48 h and peaked at 1 week; paralleled by enhanced expression of pronociceptive neuropeptides in the spinal cord. Morphine and tramadol significantly attenuated hyperalgesia and allodynia, while not significantly altering motor coordination/sedation. These data indicate dual mechanism therapeutics may be effective for treating pain associated with burns.


Subject(s)
Analgesics, Opioid/pharmacology , Burns/metabolism , Calcitonin Gene-Related Peptide/metabolism , Hyperalgesia/metabolism , Morphine/pharmacology , Nociception/drug effects , Spinal Cord/metabolism , Substance P/metabolism , Tramadol/pharmacology , Animals , Behavior, Animal , Burns/complications , Burns/pathology , Disease Models, Animal , Hyperalgesia/etiology , Male , Nociceptive Pain/etiology , Nociceptive Pain/metabolism , Pain/etiology , Pain/metabolism , Rats , Rats, Sprague-Dawley
20.
Glob Adv Health Med ; 1(4): 16-31, 2012 Sep.
Article in English | MEDLINE | ID: mdl-24278828

ABSTRACT

The development and implementation of competent and cost-effective computerized medical records that profoundly improve physician productivity and knowledge management will require the development of a new paradigm for the representation and analysis of medical knowledge and logic. Medical knowledge is acquired inductively by observing, measuring, and eliciting information from patients in a process that is investigational rather than transactional. Most, if not all, current approaches to health information technology (HIT) rely on a logic and data structure that imposes significant limitations on the ability of physicians to thoroughly and efficiently document and access empiric patient data because the information is almost invariably organized in a way which presumes, rather than makes explicit, the relationships of concepts and their meaning. Cmapping provides a graphical method of capturing and displaying expert content knowledge that is simple to comprehend and modify and provides a foundation for a dynamic, inductive, and inclusive method of clinical documentation and research. The basis of medical decision analysis along with representative samples of medical knowledge modeling in the Cmap format is presented. The knowledge structures that are captured in Cmaps can be expressed directly in propositional logic, enabling the capability to convert Cmapped clinical expressions to be used to define a description logic for clinical evidence documentation and analysis that can in turn be mapped to multiple natural languages. The described description logic approach can be used to formulate digital messages and documents and to automate the process of converting description specifications formulated in propositional logic into operational electronic health record solutions for capture and reporting of clinical encounters. It has also been demonstrated that using Cmaps to elicit content knowledge from physicians to build point-of-care clinical documentation screens can significantly reduce the time and costs necessary to implement the physician's knowledge into operational systems and that using Cmaps eliminates the need for HIT expertise in the rules-encoding process.


Para elaborar y aplicar historias clínicas informatizadas competentes y rentables, que mejoren notablemente la productividad de los médicos y la gestión de la información, es necesario crear un nuevo paradigma para la representación y el análisis del conocimiento médico y la lógica. El conocimiento médico se adquiere de forma inductiva, mediante la observación, la medición y la recogida de información de los pacientes en un proceso que es más experimental que transaccional. La mayoría de las estrategias actuales de las tecnologías de la información sanitaria (TIS), si no todas, dependen de una estructura lógica y de datos que limita de manera considerable la capacidad de los médicos a la hora de documentar y acceder de forma eficiente y exhaustiva los datos empíricos de los pacientes, ya que la información está casi siempre organizada de modo tal que supone, en lugar de hacer explícitas, las relaciones entre los conceptos y su significado. La utilización de mapas conceptuales proporciona un método gráfico de captura y presentación de información de contenido experto, el cual resulta sencillo de comprender y modificar y, además, sienta las bases de un método dinámico, inductivo e integrador de la documentación e investigación clínicas. Los fundamentos del análisis de las decisiones médicas, junto con la creación de modelos de muestras representativas del conocimiento médico, se presentan en forma de mapa conceptual. Las estructuras de la información capturadas en los mapas conceptuales se pueden expresar directamente mediante la lógica proposicional, de forma que permita convertir las expresiones clínicas a utilizar en mapas conceptuales, a fin de definir una lógica descriptiva para la documentación y el análisis de las evidencias clínicas que, a su vez, se pueden cartografiar en múltiples lenguajes naturales. Este planteamiento de lógica descriptiva se puede emplear para elaborar mensajes y documentos digitales y para automatizar el proceso de conversión de especificaciones descriptivas formuladas en lógica proposicional en soluciones electrónicas operativas de historias clínicas destinadas a la captura y notificación de las visitas clínicas. También se ha mostrado que mediante mapas conceptuales destinados a obtener conocimientos de contenidos a partir de los médicos, con el fin de crear pantallas de documentación clínica en el lugar de atención, se puede reducir significativamente el tiempo y los costes necesarios para introducir el conocimiento del médico en los sistemas operativos, y que, mediante los mapas conceptuales, se elimina la necesidad de experiencia en el uso de las TIS a la hora de procesar la codificación de reglas.

SELECTION OF CITATIONS
SEARCH DETAIL
...